An antibody that neutralizes SARS-CoV-1 and SARS-CoV-2 by binding to a conserved spike epitope outside the receptor binding motif

The rapid evolution of SARS-CoV-2 viruses, such as the Omicron variants which are highly transmissible and immune evasive, underscores the need to develop therapeutic antibodies with broad neutralizing activities. Here, we used the LIBRA-seq technology, which identified SARS-CoV-2 specific B cells v...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Yan, Sun, Pengcheng, Xie, Xuping, Du, Mingjian, Du, Fenghe, Ye, Jianfeng, Kalveram, Birte K., Plante, Jessica A., Plante, Kenneth S., Li, Bo, Bai, Xiao-chen, Shi, Pei-Yong, Chen, Zhijian J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9407945/
https://www.ncbi.nlm.nih.gov/pubmed/35926067
http://dx.doi.org/10.1126/sciimmunol.abp9962

Ejemplares similares

Ejemplares similares